Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Kikuchi, Jiro ^a   Shibayama, Naoya ^a   Yamada, Satoshi ^a   Wada, Taeko ^a   Nobuyoshi, Masaharu ^a   Izumi, Tohru ^b   Akutsu, Miyuki ^b   Kano, Yasuhiko ^b   Sugiyama, Kanako ^c   Ohki, Mio ^c   Park, Sam Yong ^c   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[4 (3,4,5 TRIMETHOXYPHENYL)BUTYL]HOMOPIPERAZINE; BORTEZOMIB; HEXAHYDRO 1,4 DIAZEPINE DERIVATIVE; K 10228; K 10252; K 10256; K 10310; K 10487; K 10552; K 7174; K 7220; N,N' BIS[3 (3,4,5 TRIMETHOXYPHENYL)PROPYL]HOMOPIPERIZINE; N,N' BIS[4 (3,4,5 TRIMETHOXYNAPHTHYL)BUTYL]HOMOPIPERIZINE; N,N' BIS[4 (3,4,5 TRIMETHOXYPHENYL)BUTYL]HOMOPIPERIZINE; N,N' BIS[5 (2,3,4,5 TETRAMETHOXYPHENYL) 4 PENTENYL]HOMOPIPERIZINE; N,N' BIS[5 (3,4,5 TRIMETHOXYPHENYL) 4 PENTENYL] 6 METHOXYHOMOPIPERIZINE; N,N' BIS[5 (3,4,5 TRIMETHOXYPHENYL) 4 PENTENYL]HOMOPIPERIZINE; N,N' BIS[6 (3,4,5 TRIMETHOXYPHENYL) 4 OXO 5 HEXENYL]HOMOPIPERIZINE; N,N' BIS[7 (3,4,5 TRIMETHOXYPHENYL) 5 OXO 6 HEPTENYL]HOMOPIPERIZINE; PROTEASOME; PROTEASOME BETA 1 SUBUNIT; PROTEASOME BETA 2 SUBUNIT; PROTEASOME BETA 5 SUBUNIT; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; MOLECULAR INTERACTION; MYELOMA CELL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; IMMUNOBLOTTING; NEOPLASMS; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84876154755     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060649     Document Type: Article

References (52)

1. Sawyers C, (2004) Targeted cancer therapy. Nature 432: 294-297.
2. Weissman AM, Shabek N, Ciechanover A, (2011) The predator becomes the prey: regulating the ubiquitin system by ubiquitination and degradation. Nat Rev Mol Cell Biol 12: 605-620.
3. Frankland-Searby S, Bhaumik SR, (2012) The 26S proteasome complex: An attractive target for cancer therapy. Biochem Biophys Acta 1825: 64-76.
4. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, et al. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8: 1053-1072.
5. Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, et al. (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 116: 406-417.
6. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JK, et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119: 1450-1458.
7. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, et al. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12: 591-599.
8. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, et al. (2009) Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 28: 231-242.
9. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 359: 906-917.
10. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, et al. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 28: 5101-5109.
11. Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, et al. (2011) A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 118: 6274-6283.
12. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, et al. (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106: 3777-3784.
13. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, et al. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24: 3113-3120.
14. Lu S, Yang J, Song X, Gong S, Zhou H, et al. (2008) Point mutation of the proteasome 5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 326: 423-431.
15. Oerlemans R, Franke NE, Assaraf YG, Assaraf YG, Cloos J, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit ß5 (PSMB5) gene mutation and over-expression of PSMB5 protein. Blood 112: 2489-2499.
16. Lu S, Yang J, Chen Z, Gong S, Zhou H, et al. (2009) Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 37: 831-837.
17. Ri M, Iida S, Nakashima T, Miyazaki T, Mori F, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512.
18. Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, et al. (2011) Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One 6: e27996.
19. Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, et al. (2012) Impaired bortezomib binding to mutant ß5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26: 757-768.
20. Kitakaze M, Minamino T, Node K, Takashima S, Funaya H, et al. (1999) Adenosine and cardioprotection in the diseased heart. Jpn Circ J 63: 231-243.
21. Umetani M, Nakao H, Doi T, Iwasaki A, Ohtaka M, et al. (2000) A novel cell adhesion inhibitor, K-7174, reduces the endothelial VCAM-1 induction by inflammatory cytokines, acting through the regulation of GATA. Biochem Biophys Res Commun 272: 370-374.
22. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, et al. (2003) A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1ß, TNF-α, or L-NMMA. FASEB J 17: 1742-1744.
23. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, et al. (2004) Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 104: 4300-4307.
24. Takano Y, Hiramatsu N, Okamura M, Hayakawa K, Shimada T, et al. (2007) Suppression of cytokine response by GATA inhibitor K-7174 via unfolded protein response. Biochem Biophys Res Commun 360: 470-475.
25. Drexler HG, Matsuo Y, MacLeod RA, (2003) Persistent use of false myeloma cell lines. Hum Cell 16: 101-105.
26. Uno K, Inukai T, Kayagaki N, Goi K, Sato H, et al. (2003) TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101: 3658-3667.
27. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, et al. (2004) Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 13: 1827-1837.
28. Mitsunaga K, Kikuchi J, Wada T, Furukawa Y, (2012) Latexin Regulates the abundance of multiple cellular proteins in hematopoietic stem cells. J Cell Physiol 227: 1138-1147.
29. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, et al. (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96: 10403-10408.
30. Smith DM, Wang Z, Kazi A, Li LH, Chan,TH, et al, (2002) Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 8: 382-392.
31. Otwinowski Z, Minor W, (1997) Processing of X-ray diffraction data collection in oscillation mode. Method Enzymol 276: 307-326.
32. Vagin A, Teplyakov A, (2000) An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr 56: 1622-1624.
33. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948-1954.
34. Emsley P, Cowtan K, (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
35. Davis IW, Murray LW, Richardson JS, Richardson DC, (2004) MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res 32: W615-619 doi:10.1093/nar/gkh398.
36. Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, et al. (2007) E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells 25: 2439-2447.
37. Wada T, Kikuchi J, Furukawa Y, (2012) Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Rep 13: 142-149.
38. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, et al. (2007) Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus-negative leukemia cell lines. Leukemia 21: 1005-1014.
39. Groll M, Berkers CR, Ploegh HL, Ovaa H, (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20 S proteasome. Structure 14: 451-456.
40. De Bettignies G, Coux O, (2010) Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 92: 1530-1545.
41. Ruschak AM, Slassi M, Kay LE, Schimmer AD, (2011) Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103: 1007-1017.
42. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, et al. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110: 3281-3290.
43. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, et al. (2009) A phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematological malignancies. Clin Cancer Res 15: 7085-7091.
44. Chauhan D, Catley L, Li G, Podar K, Hideshima T, et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8: 407-419.
45. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, et al. (2008) CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111: 2765-2775.
46. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, et al. (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70: 1970-1980.
47. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, et al. (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116: 4906-4915.
48. Millward M, Price T, Townsend A, Sweeney C, Spencer A, et al. (2012) Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs 30: 2303-2317.
49. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, et al. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120: 947-959.
50. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, et al. (2011) In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17: 5311-5321.
51. Mujtaba T, Dou QP, (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 12: 471-480.
52. Groll M, Huber R, Potts BC, (2006) Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20 S proteasome reveal important consequences of ß-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128: 5136-5141.